| Vaccine description | |
|---|---|
| Target | H5N8 |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Zoonotic Influenza Vaccine Seqirus |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
AnH5N8 vaccine is aninfluenza vaccine intended to provideacquired immunity against H5 subtype influenza A viruses.[1] It is given viaIntramuscular injection.[1]
Zoonotic influenza vaccine Seqirus is authorized for use in the European Union.[1] It contains a flu strain called A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b).[1] Zoonotic influenza vaccine Seqirus was considered to be the best candidate to provide protection against circulating H5 influenza A strains.[1]
The most common side effects include reactions at the site of injection (swelling, pain, redness and hardening of the skin), myalgia (muscle pain), headache, tiredness, chills and feeling generally unwell.[1]
Zoonotic Influenza Vaccine Seqirus H5N8 isindicated for active immunization against H5 subtype influenza A viruses in adults 18 years of age and older.[1]
The European Commission arranged for a supply of zoonotic influenza vaccine.[2]
